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An Interaction Between Keratin 10 and the Cornified Cell Envelope 
In this Issue, Ming et al (p. 780) find that the keratin intermediate 
filame nt K ID is a transglutaminase substrate and is tightly bound to 
the cornified cell envelope. The keratin fil amentous network forms 
rhe structural scaffold in all epidermal cells, giving these cells the 
necessary tensi le strength to withstand the physical forces to which 
rhe epidermis is exposed. The cornified cell envelope consists of a 
layer of cross-linked proteins deposited beneath the granular and 
stratum corneum cell membranes, which gives these cells rigidity, 
and a layer of lipids deposited between these cel ls, which provides 
the water barrier for the epidermis. KlO, one member of the keratin 
fami ly, is first expressed in the spinous layer's fil amentous network, 
but is present throughout the suprabasal cell layers of the epidermis. 
Previously, it has been shown that point mutations in keratin genes 
produce defective proteins and that epidermal cells expressing these 
defective keratins are so fragi le they actually rupture under stress. 
Such mutations have been shown to cause epidermal blistering dis-
eases, such as epidermolytic hyperkeratosis (EHK) (mutations in KI 
or K1D) and epidermolysis bullosa simplex (EBS) (mutations in K5 
or KI4). Other studies have shown that the protein component of 
the cornified cell envelope, which appears late in epidermal differ-
entiation as a dense band at the membranes of the granu lar and 
stratum corneum cells, is resistant to proteolytic cleavage and harsh 
chemical extrac tion methods. In addition, the proteins deposited 
beneath the cell membranes are highl y cross-linked by transgluta-
minases. Ming et al began their research looking for new cornified 
envelope proteins by screening for transglutaminase substrates. To 
their surprise, they found that KIO is a substrate for transglutamin-
ase and that it is tightly bound to the cornified cell envelope. In 
doing so, they bring together the keratin and the cornified cell 
envelope fi elds of research and provide a model with which to study 
the interaction of the keratins and the cell envelope proteins and 
their contribution to the tensile strength of the stratum corneum. 
Single Point Mutation in Keratin 1 Found in Non-Epidermolytic 
Palmar-Plantar Keratoderma 
In examining patients with palmar-plantar keratoderma (PPK), 
Kimonis et al (p. 764) report a new mutation in the variable end 
domain region of the keratin I gene resulting in hyperkeratosis but 
no cell lysis. All previously described mutations in keratins (and 
there have been over 50 different substitutions found) have been in 
the keratin central rod domain or the adjacent HI domain, regions 
known to be involved in assembly and stabili ty of the keratin inter-
mediate fil ament. Such mutations have been found to cause epider-
mal blistering diseases, including epidermolysis bullosa simplex, 
epidermolytic hyperkeratosis, ichthyosis buUosa of Siemens, and 
rhe epidermolytic type ofPPK, which shows mutations in keratin 9. 
In all of these cases, the cellular degeneration or disruption can be 
attributed to defective keratin interactions and filament asse mbly. In 
contrast, the mutation described here occurs not in the rod domain, 
but in the variable amino-terminal end domain of keratin 1. In 
addi tion, the disease, non-epidermolytic PPK, shows the distinct 
fea ture of hyperkeratosis without epidermolysis, which distin-
guishes it from the epidermolytic type PPK. These findin gs are 
consistent with the idea that the variable region of the keratin pro-
tein has a role other than in filament stability. With this in mind, 
Kimonis et al conclude that the amino-terminal domains of keratins 
may be involved in specific interactions with other cel lular compo-
nents, such as desmosomes, and that the hyperkeratosis associated 
with this mutation may be due to the perturbation of these interac-
tions. 
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Alopecia Areata: An HLA Restricted Autoimmune Disease? 
Welsh et af (p. 758) report here that American Caucasians with 
alopecia areata have a highly significant increase in specific HLA-
class II antigens. Alopecia areata, a disease in which patients show 
loss of hair in patches, is associated with thyroiditis and diabetes. In 
addition, T cells infiltrate around the diseased hair follicles, a pro-
cess usually suggestive of a delayed hypersensitivity reaction. Even 
though an autoimmune mechanism has been previously suggested, 
the data supporting this conclusion have been inc~nclusive, l.eaving 
the cause of alopecia areata a controversy. In autOlmmune dlseases, 
HLA class II chain sequences bind and present peptide antigens of 
T-cell receptors and thus are crucial determinants for the immune 
response. To better understand the role of HLA class II genes in 
disease susceptibility, Welsh and her colleagues apply a polymerase 
chain reaction (PCR) method, which allows determination of the 
allelic DNA sequences, to blood samples from patients exhibiting 
alopecia. This method, which is more sensitive than the serologic 
typing done in the past, uses hybridization of allelic-specific oligo-
nucleotide probes to amplified genomic DNA and thus allows ex-
amination of many HLA alleles. They find that specific DQB alleles 
may be absent from alopecia areata, whereas combination of specific 
DQB and DQA alleles are found in the more severe cases of alopecia 
totalis and alopecia universalis. The results reported here substan-
tiate the concept that alopecia areata is an autoimmune disease, and, 
further, that more than one HLA allele can influence susceptibility 
to or possibly persistence of alopecia areata. 
Distinct T-Cell Populations in Basal Cell and Squamous Cell Carcinomas 
Addressing the nature of the T-cell infiltrate in basal cell carcinoma 
(BCC) and in squamous cell carcinoma (SCC), Ohmenetaf (p. 751) 
find that distinct T cells infiltrate the tumors, as compared to blood 
or uninvolved skin. BCC and SCC are the most common tumors 
diagnosed in the United States, with an ever-increasing incidence. 
Several studies have demonstrated the importance of the immune 
system in the control of these cancers but have not defined the 
specific T-cell response, although such identification is critical to 
understanding the pathogenesis of these tumors. T cells are known 
to recognize antigen through their T-cell receptor, which is com-
posed of an a and a p chain. There are several gene segments encod-
ing both chains, and by examining the relative occurrence of the p 
chains, it is possible to determine the repertoire expressed by the T 
cells of interest. Using the polymerase chain reaction (PCR) 
method, the authors have identified the T-cell receptor gene seg-
ments on small tumor biopsies. Their data corroborate the concept 
that resident skin T cells have a distinct receptor repertoire and 
further suggest that some of the tumor specific T cells may come 
from this unique compartment. These results set the ground work 
for identification of tumor specific antigen of BCC and SCC and 
further examination of the role ofT cells in the immune response to 
these tumors. 
Retinoic Acid and Retinaldehyde, a Natural Metabolite 
In this issue, two papers report the effects of topical application of 
retinoic acid or the natural metabolite, retinaldehyde, on human 
skin. Meunier et af (p. 775) find that four applications of a 0.1 % 
solution of retinoic acid upregulates important cell surface mole-
cules involved in antigen binding and presentation to T cells, 
whereas Saurat and colleagues (p. 770) report that retinaldehyde, a 
natural metabolite of vitamin A, is well tolerated and allows long-
term use in patients with inflammatory dermatoses. The retinoid 
and steroid receptor families are powerful regulators of cellular 
responsiveness and differentiation status. In the epidermis, the Lan-
gerhans cells are the major antigen-presenting cells, and Meunier 
and co-workers find that topical retinoic acid causes a change in 
phenotype and functional status of the Langerhans cells. This 
change is distinct from the changes observed in mature Langerhans 
cells and dendritic cells and from the hyperstimulatory status of 
Langerhans cells in diseases such as atopic dermatitis. Specifically, 
the authors find an increase in specific cell surface molecules, and 
one (CDllc) is critical for Langerhans cells to present antigen to T 
cells. In addition, this increase in Langerhans cells presentation of 
foreign antigen was not so great as to induce the autoreactive re-
sponses to self antigens. Saurat et a1 report on the irritation aspect of 
topical application of retinoic acid (RA) and present data supporting 
the use of retinal de hyde which targets differentiating keratinocytes. 
They postulate that the irritation is due to an overload of the RA-
dependent pathway and that using an immediate RA precursor, such 
as retinaldehyde, may prevent this overload. Human keratinocytes 
enzymatically transform retinaldehyde into RA, with the conver-
sion rate higher in differentiated than in undifferentiated cells. The 
authors report here that even though retinaldehyde is an aldehyde, 
it has biologic activity, is not a strong sensitizer, and does show 
retinoid-like activity. In addition, they report a pilot study that 
shows that patients clearly tolerated various concentrations of topi-
cal retinaldehyde. Thus, retinoic acid may present a safe method for 
upregulating cutaneous immune response when needed. On the 
other hand, if no immune response is wanted, retinaldehyde may 
represent a novel way to deliver retinoid activity to treat skin dis-
eases. 
